Syntax Bio, a Chicago, IL-based preclinical-stage biotechnology company, raised a funding round of undisclosed amount.
Backers included Astellas Venture Management and Illumina Ventures, as well as DCVCBio, Civilization Ventures, EGB Capital, and Portal Innovations.
To date, Syntax Bio has raised $15m to advance its cell differentiation discovery platform.
Co-founded by Ryan Clarke, PhD, and Professor Brad Merrill, PhD, from the University of Illinois at Chicago, Syntax Bio is a preclinical-stage biotechnology company that is focused on generating therapeutic-grade cells from stem cells leveraging its novel Cellgorithm platform technology. Its Cellgorithm platform mimics human developmental processes at the epigenetic level, using a modified CRISPR system to regulate endogenous genes in an automatic and temporally controlled manner.
FinSMEs
18/09/2024